



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2347247 A1 2000/04/20

(21) **2 347 247**

(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 1999/10/13  
(87) Date publication PCT/PCT Publication Date: 2000/04/20  
(85) Entrée phase nationale/National Entry: 2001/04/12  
(86) N° demande PCT/PCT Application No.: IB 99/01678  
(87) N° publication PCT/PCT Publication No.: WO 00/22166  
(30) Priorités/Priorities: 1998/10/14 (60/104,302) US;  
1998/10/14 (60/104,286) US

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C12Q 1/68, C07K 14/72, C07K 14/705,  
C12N 9/64, C12N 9/02  
(71) Demandeur/Applicant:  
PYROSEQUENCING AB, SE  
(72) Inventeurs/Inventors:  
JONSSON, LENA, SE;  
LINDSTROM, PER HARRY RUTGER, SE;  
ANDERSSON, MARIA KRISTINA, SE;  
NORBERG, LEIF TORBJORN, SE  
(74) Agent: SMART & BIGGAR

(54) Titre : GENES D'EVALUATION D'ETAT CARDIO-VASCULAIRE ET COMPOSITIONS D'UTILISATIONS  
ASSOCIEES  
(54) Title: GENES FOR ASSESSING CARDIOVASCULAR STATUS AND COMPOSITIONS FOR USE THEREOF

(57) Abrégé/Abstract:

The present invention provides methods for assessing cardiovascular status in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding ACE, AT1, AGT, renin, aldosterone synthase, type-2 angiotensin II receptor, endothelin receptor, and  $\beta$ -adrenoceptor. The invention also provides isolated nucleic acids encoding polymorphisms in genes encoding ACE, AT1, AGT, renin, aldosterone synthase, type-2 angiotensin II receptor, endothelin receptor and  $\beta$ -adrenoceptor, nucleic acid probes that hybridized to polymorphic positions, kits for the prediction of cardiovascular status, and nucleic acid and peptide targets for use in identifying candidate cardiovascular drugs.

BEST AVAILABLE COPY

